FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011491811> ?p ?o ?g. }

• W2011491811 abstract "You have accessJournal of UrologyKidney Cancer: Basic Research II1 Apr 2015MP47-20 IDENTIFICATION OF ACTIONABLE TARGETS IN CHROMOPHOBE RENAL CELL CARCINOMA DETECTED BY MULTIPLATFORM MOLECULAR ANALYSIS Philip Abbosh, Sherri Millis, Nancy Doll, Adam Hauben, Sandeep Reddy, Daniel Geynisman, and Robert Uzzo Philip AbboshPhilip Abbosh More articles by this author , Sherri MillisSherri Millis More articles by this author , Nancy DollNancy Doll More articles by this author , Adam HaubenAdam Hauben More articles by this author , Sandeep ReddySandeep Reddy More articles by this author , Daniel GeynismanDaniel Geynisman More articles by this author , and Robert UzzoRobert Uzzo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1540AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Chromophobe renal cell carcinoma (chRCC) is a rare kidney cancer subtype that infrequently metastasizes or recurs after definitive local therapy. Limited biomarker data exists to prognosticate outcome or predict response to therapy. We explored the utility of a CLIA-certified biomarker panel which uses immunohistochemistry (IHC) and targeted next generation sequencing (tNGS) to assess presence of druggable targets with the intent of developing targeted therapy protocols in patients with (chRCC). Because of the non-aggressive nature of small chRCCs, we excluded T1a tumors. METHODS Cases were identified from 65,000+ tumors submitted for commercial testing at Caris Life Sciences. All tissues were internally reviewed by a dedicated genitourinary pathologist to confirm diagnosis. Markers were analyzed on tumor tissue removed during partial or radical nephrectomy. IHC was performed on 19 proteins. FISH was performed on EGFR, HER2, and TOP2A. tNGS was performed on 47 genes. RESULTS Twelve patients with chRCC underwent biomarker panel testing. Five patients had metastatic disease. Median age was 54 years old; 50% of patients were male. One patient had a T1b tumor, two patients had T2 tumors, 8 patients had T3 tumors, and one had a T4 tumor. Thymidylate synthase (TS), ribonucleotide reductase M1 (RRM1), and O-6-methylguanine-DNA methyltransferase (MGMT) expression was absent in 12/12, 11/12 and 11/12 tumors, respectively. PTEN expression was absent in 7/12 of tumors. cKIT and PDGFR was expressed in 6/9 and 0/4 tumors, respectively. Lastly, point mutations in APC and TP53 were detected in 1/7 and 3/7 tumors, respectively. No mutations were identified in the other 45 genes tested and no changes in copy number were identified. CONCLUSIONS Biomarker analysis showed that advanced chRCC might be amenable to chemotherapy with 5-fluorouracil, gemcitabine, or temozolamide because of absent TS, RRM1, and MGMT expression, respectively. Such rationale has been used successfully in targeted treatment of other cancers. In addition, sunitinib or imatinib but not sorafenib might be preferred tyrosine kinase inhibitors, as cKIT but not PDGFR was detected. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e559 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Philip Abbosh More articles by this author Sherri Millis More articles by this author Nancy Doll More articles by this author Adam Hauben More articles by this author Sandeep Reddy More articles by this author Daniel Geynisman More articles by this author Robert Uzzo More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W2011491811 created "2016-06-24" @default.
• W2011491811 creator A5000799237 @default.
• W2011491811 creator A5011122559 @default.
• W2011491811 creator A5023841340 @default.
• W2011491811 creator A5033372450 @default.
• W2011491811 creator A5043554307 @default.
• W2011491811 creator A5046522995 @default.
• W2011491811 creator A5077908907 @default.
• W2011491811 date "2015-04-01" @default.
• W2011491811 modified "2023-10-18" @default.
• W2011491811 title "MP47-20 IDENTIFICATION OF ACTIONABLE TARGETS IN CHROMOPHOBE RENAL CELL CARCINOMA DETECTED BY MULTIPLATFORM MOLECULAR ANALYSIS" @default.
• W2011491811 cites W2010991736 @default.
• W2011491811 doi "https://doi.org/10.1016/j.juro.2015.02.1540" @default.
• W2011491811 hasPublicationYear "2015" @default.
• W2011491811 type Work @default.
• W2011491811 sameAs 2011491811 @default.
• W2011491811 citedByCount "0" @default.
• W2011491811 crossrefType "journal-article" @default.
• W2011491811 hasAuthorship W2011491811A5000799237 @default.
• W2011491811 hasAuthorship W2011491811A5011122559 @default.
• W2011491811 hasAuthorship W2011491811A5023841340 @default.
• W2011491811 hasAuthorship W2011491811A5033372450 @default.
• W2011491811 hasAuthorship W2011491811A5043554307 @default.
• W2011491811 hasAuthorship W2011491811A5046522995 @default.
• W2011491811 hasAuthorship W2011491811A5077908907 @default.
• W2011491811 hasConcept C126322002 @default.
• W2011491811 hasConcept C142724271 @default.
• W2011491811 hasConcept C143998085 @default.
• W2011491811 hasConcept C204232928 @default.
• W2011491811 hasConcept C2777472916 @default.
• W2011491811 hasConcept C2778560582 @default.
• W2011491811 hasConcept C2780091579 @default.
• W2011491811 hasConcept C2780227381 @default.
• W2011491811 hasConcept C2781197716 @default.
• W2011491811 hasConcept C2781278892 @default.
• W2011491811 hasConcept C55493867 @default.
• W2011491811 hasConcept C71924100 @default.
• W2011491811 hasConcept C78795084 @default.
• W2011491811 hasConcept C86803240 @default.
• W2011491811 hasConceptScore W2011491811C126322002 @default.
• W2011491811 hasConceptScore W2011491811C142724271 @default.
• W2011491811 hasConceptScore W2011491811C143998085 @default.
• W2011491811 hasConceptScore W2011491811C204232928 @default.
• W2011491811 hasConceptScore W2011491811C2777472916 @default.
• W2011491811 hasConceptScore W2011491811C2778560582 @default.
• W2011491811 hasConceptScore W2011491811C2780091579 @default.
• W2011491811 hasConceptScore W2011491811C2780227381 @default.
• W2011491811 hasConceptScore W2011491811C2781197716 @default.
• W2011491811 hasConceptScore W2011491811C2781278892 @default.
• W2011491811 hasConceptScore W2011491811C55493867 @default.
• W2011491811 hasConceptScore W2011491811C71924100 @default.
• W2011491811 hasConceptScore W2011491811C78795084 @default.
• W2011491811 hasConceptScore W2011491811C86803240 @default.
• W2011491811 hasIssue "4S" @default.
• W2011491811 hasLocation W20114918111 @default.
• W2011491811 hasOpenAccess W2011491811 @default.
• W2011491811 hasPrimaryLocation W20114918111 @default.
• W2011491811 hasRelatedWork W2024184727 @default.
• W2011491811 hasRelatedWork W2034555737 @default.
• W2011491811 hasRelatedWork W2038759101 @default.
• W2011491811 hasRelatedWork W2047131672 @default.
• W2011491811 hasRelatedWork W2321711202 @default.
• W2011491811 hasRelatedWork W2920200983 @default.
• W2011491811 hasRelatedWork W3040274980 @default.
• W2011491811 hasRelatedWork W3094602543 @default.
• W2011491811 hasRelatedWork W3193779882 @default.
• W2011491811 hasRelatedWork W2086981116 @default.
• W2011491811 hasVolume "193" @default.
• W2011491811 isParatext "false" @default.
• W2011491811 isRetracted "false" @default.
• W2011491811 magId "2011491811" @default.
• W2011491811 workType "article" @default.